Mutation Analysis and Single Nucleotide Polymorphism of TP53 Gene in Breast Cancer in East Java

Rizqa Radhiyah, I Kade Karisma Gita Ardana, Wisnubroto Wisnubroto, Dwi Listyorini, Hendra Susanto

Abstract


The Incidence of Indonesia breast cancer case in 2018 was reported at 20.7% or 160,653 in number. The factors that caused breast cancer is TP53 gene mutation and Single Nucleotide Polymorphism (SNP). This study aimed to determine the mutation and Single Nucleotide Polymorphism (SNP) of TP53 gene in breast cancer. Samples of this study were 9 people chosen based on a purposive technique. The methods include total DNA isolation, DNA quantification, PCR, and sequencing. The results of the sequencing were then analyzed using alignment and blast. The SNP is browsed by the SNP finder on NCBI both followed by protein modeling. The results of this study indicate the existence of mutation in the exon and intron regions. Substitution of Guanine (G) to base Adenine (A) is occur in codon 496 which is a coding region. SNP was also obtained in exon of sample 12. The conclusion of this study is breast cancer can be caused by mutations that occur in the exon and altered the structur of protein structure, so then affect the binding affinity between p53 and its target domain. Tp53 gene mutation is not the only cause of breast cancer staging development, there are other genes that also contribute to the development of cancer stage. In addition, Single Nucleotide Polymorphism in the TP53 gene can be used as a predisposition marker of breast cancer that has potential to be inherited

Keywords


TP53, Breast Cancer, Mutation, Single Nucleotide Polymorphism

Full Text:

PDF

References


M. M. Shams-White et al., “Operationalizing the 2018 world cancer research fund/american institute for cancer research (WCRF/AICR) cancer prevention recommendations: A standardized scoring system,” Nutrients, vol. 11, no. 7, 2019, doi: 10.3390/nu11071572.

Y. Feng et al., “Breast cancer development and progression: Risk factors, cancer stem cells, signaling pathways, genomics, and molecular pathogenesis,” Genes Dis., vol. 5, no. 2, pp. 77–106, 2018, doi: 10.1016/j.gendis.2018.05.001.

World Health Organization, “Indonesia Source GLOBOCAN 2018,” Int. Agency Res. Cancer, vol. 256, pp. 1–2, 2019.

Kementrian Kesehatan RI, “Pusat Data dan Informasi Kesehatan Kementerian Kesehatan Republik Indonesia: Stop Kanker,” 2015.

D. S. Wishart, “Is Cancer a Genetic Disease or a Metabolic Disease?,” EBioMedicine, vol. 2, no. 6, pp. 478–479, 2015, doi: 10.1016/j.ebiom.2015.05.022.

D. Ly, D. Forman, J. Ferlay, L. A. Brinton, and M. B. Cook, “An international comparison of male and female breast cancer incidence rates,” Int. J. Cancer, vol. 132, no. 8, pp. 1918–1926, 2013, doi: 10.1002/ijc.27841.

M. Olivier, R. Eeles, M. Hollstein, M. A. Khan, C. C. Harris, and P. Hainaut, “The IARC TP53 database: New online mutation analysis and recommendations to users,” Human Mutation. 2002, doi: 10.1002/humu.10081.

R. Eachkoti et al., “BRCA1 and TP53 mutation spectrum of breast carcinoma in an ethnic population of Kashmir, an emerging high-risk area,” Cancer Lett., 2007, doi: 10.1016/j.canlet.2006.08.012.

K. A. Hill and S. S. Sommer, “p53 as a mutagen test in breast cancer,” in Environmental and Molecular Mutagenesis, 2002, doi: 10.1002/em.10065.

M. J. O’Connor, “Targeting the DNA Damage Response in Cancer,” Mol. Cell, vol. 60, no. 4, pp. 547–560, 2015, doi: 10.1016/j.molcel.2015.10.040.

A. B. Williams and B. Schumacher, “p53 in the DNA-damage-repair process,” Cold Spring Harb. Perspect. Med., vol. 6, no. 5, pp. 1–15, 2016, doi: 10.1101/cshperspect.a026070.

J. D. Davis, “DNA damage and breast cancer,” World J. Clin. Oncol., vol. 2, no. 9, p. 329, 2011, doi: 10.5306/wjco.v2.i9.329.

P. Arizti et al., “Tumor Suppressor p53 Is Required To Modulate BRCA1 Expression,” Mol. Cell. Biol., vol. 20, no. 20, pp. 7450–7459, 2000, doi: 10.1128/mcb.20.20.7450-7459.2000.

E. R. Kastenhuber and S. W. Lowe, “Putting p53 in Context,” Cell, vol. 170, no. 6, pp. 1062–1078, 2017, doi: 10.1016/j.cell.2017.08.028.

K. Hientz, A. Mohr, D. Bhakta-Guha, and T. Efferth, “The role of p53 in cancer drug resistance and targeted chemotherapy,” Oncotarget, vol. 8, no. 5, pp. 8921–8946, 2017, doi: 10.18632/oncotarget.13475.

K. M. Mahdi, M. R. Nassiri, and K. Nasiri, “Hereditary genes and SNPs associated with breast cancer,” Asian Pacific J. Cancer Prev., vol. 14, no. 6, pp. 3403–3409, 2013, doi: 10.7314/APJCP.2013.14.6.3403.

M. A. De Bruin, J. M. Ford, and A. W. Kurian, “Genetic polymorphisms as predictors of breast cancer risk,” Curr. Breast Cancer Rep., vol. 4, no. 4, pp. 232–239, 2012, doi: 10.1007/s12609-012-0091-7.

A. Shamseddine, A. Tfayli, S. Temraz, and R. Abou Mrad, “Breast cancer in low- and middle-income countries: An emerging and challenging epidemic,” Journal of Oncology. 2010, doi: 10.1155/2010/490631.

P. Marchetti et al., “Prognostic value of p53 molecular status in high-risk primary breast cancer,” Ann. Oncol., vol. 14, no. 5, pp. 704–708, 2003, doi: 10.1093/annonc/mdg197.

L. N. Shulman, W. Willett, A. Sievers, and F. M. Knaul, “Breast cancer in developing countries: Opportunities for improved survival,” J. Oncol., 2010, doi: 10.1155/2010/595167.

A. Colomer et al., “Lack of p53 nuclear immunostaining is not indicative of absence of TP53 gene mutations in colorectal adenocarcinomas,” Appl. Immunohistochem. Mol. Morphol., vol. 11, no. 2, pp. 130–137, 2003, doi: 10.1097/00129039-200306000-00007.

Z. Liu, Z. Jiang, Y. Gao, L. Wang, C. Chen, and X. Wang, “TP53 Mutations Promote Immunogenic Activity in Breast Cancer,” J. Oncol., vol. 2019, 2019, doi: 10.1155/2019/5952836.

R. Vaz-Drago, N. Custódio, and M. Carmo-Fonseca, “Deep intronic mutations and human disease,” Human Genetics. 2017, doi: 10.1007/s00439-017-1809-4.

O. Anczuków et al., “BRCA2 deep intronic mutation causing activation of a cryptic exon: Opening toward a new preventive therapeutic strategy,” Clin. Cancer Res., vol. 18, no. 18, pp. 4903–4909, 2012, doi: 10.1158/1078-0432.CCR-12-1100.

D. Ray, K. R. Murphy, and S. Gal, “The DNA binding and accumulation of p53 from breast cancer cell lines and the link with serine 15 phosphorylation,” Cancer Biol. Ther., vol. 13, no. 10, pp. 848–857, 2012, doi: 10.4161/cbt.20835.

A. Petitjean, M. I. W. Achatz, A. L. Borresen-Dale, P. Hainaut, and M. Olivier, “TP53 mutations in human cancers: Functional selection and impact on cancer prognosis and outcomes,” Oncogene, vol. 26, no. 15, pp. 2157–2165, 2007, doi: 10.1038/sj.onc.1210302.

F. A. Olotu and M. E. S. Soliman, “Dynamic perspectives into the mechanisms of mutation-induced p53-DNA binding loss and inactivation using active perturbation theory: Structural and molecular insights toward the design of potent reactivators in cancer therapy,” J. Cell. Biochem., vol. 120, no. 1, pp. 951–966, 2019, doi: 10.1002/jcb.27458.

S. Damineni et al., “Germline mutations of TP53 gene in breast cancer,” Tumor Biol., vol. 35, no. 9, pp. 9219–9227, 2014, doi: 10.1007/s13277-014-2176-6.

J. Chen, “The cell-cycle arrest and apoptotic and progression,” Cold Spring Harb. Perspect. Biol., pp. 1–16, 2016.

K. Takemura, N. Matubayasi, and A. Kitao, “Binding free energy analysis of protein-protein docking model structures by evERdock,” J. Chem. Phys., vol. 148, no. 10, 2018, doi: 10.1063/1.5019864.

R. T. Aruleba, T. A. Adekiya, B. E. Oyinloye, and A. P. Kappo, “Structural Studies of Predicted Ligand Binding Sites and Molecular Docking Analysis of Slc2a4 as a Therapeutic Target for the Treatment of Cancer,” Int. J. Mol. Sci., vol. 19, no. 2, 2018, doi: 10.3390/ijms19020386.

R. Sable and S. Jois, “Surfing the protein-protein interaction surface using docking methods: Application to the design of PPI inhibitors,” Molecules, vol. 20, no. 6, pp. 11569–11603, 2015, doi: 10.3390/molecules200611569.

K. Engeland, “Cell cycle arrest through indirect transcriptional repression by p53: I have a DREAM,” Cell Death Differ., vol. 25, no. 1, pp. 114–132, 2018, doi: 10.1038/cdd.2017.172.

K. N. Chitrala and S. Yeguvapalli, “Computational screening and molecular dynamic simulation of breast cancer associated deleterious non-synonymous single nucleotide polymorphisms in TP53 gene,” PLoS One, vol. 9, no. 8, 2014, doi: 10.1371/journal.pone.0104242.

N. Aitken, S. Smith, C. Schwarz, and P. A. Morin, “Single nucleotide polymorphism (SNP) discovery in mammals: A targeted-gene approach,” Mol. Ecol., vol. 13, no. 6, pp. 1423–1431, 2004, doi: 10.1111/j.1365-294X.2004.02159.x.

B. practice guidance for local authorities et al., “The sexual health and wellbeing of vulnerable groups in Scotland :,” Int. J. Environ. Res. Public Health, vol. 9, no. May, pp. 14–18, 2019, doi: 10.4103/jnsbm.JNSBM.

N. Gruel et al., “Lobular invasive carcinoma of the breast is a molecular entity distinct from luminal invasive ductal carcinoma,” Eur. J. Cancer, 2010, doi: 10.1016/j.ejca.2010.05.013.

L. A. Miosge et al., “Comparison of predicted and actual consequences of missense mutations,” Proc. Natl. Acad. Sci. U. S. A., vol. 112, no. 37, pp. E5189–E5198, 2015, doi: 10.1073/pnas.1511585112.

S. Kaur et al., “Analysis of TP53 polymorphisms in north Indian sporadic esophageal cancer patients,” Asian Pacific J. Cancer Prev., vol. 15, no. 19, pp. 8413–8422, 2014, doi: 10.7314/APJCP.2014.15.19.8413.




DOI: http://dx.doi.org/10.11594/jtls.11.03.12

Copyright (c) 2021 Journal of Tropical Life Science